US 12,263,175 B2
Optimised dosage of diaminophenothiazines in populations
Claude Michel Wischik, Aberdeen (GB); Bjorn Olaf Schelter, Aberdeen (GB); and Helen Christine Shiells, Aberdeen (GB)
Assigned to WisTa Laboratories Ltd., Singapore (SG)
Filed by WisTa Laboratories Ltd., Singapore (SG)
Filed on Oct. 7, 2022, as Appl. No. 17/961,961.
Application 17/961,961 is a continuation of application No. 17/262,902, previously published as PCT/EP2019/069428, filed on Jul. 18, 2019.
Claims priority of application No. 1812193 (GB), filed on Jul. 26, 2018; and application No. 1909458 (GB), filed on Jul. 1, 2019.
Prior Publication US 2023/0115931 A1, Apr. 13, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/5415 (2006.01); A23L 33/00 (2016.01); A23L 33/105 (2016.01); A23L 33/15 (2016.01); A23L 33/175 (2016.01); A23L 33/29 (2016.01); A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61K 31/13 (2006.01); A61P 25/28 (2006.01)
CPC A61K 31/5415 (2013.01) [A23L 33/105 (2016.08); A23L 33/15 (2016.08); A23L 33/175 (2016.08); A23L 33/29 (2016.08); A23L 33/30 (2016.08); A61K 9/0053 (2013.01); A61K 9/20 (2013.01); A61K 9/48 (2013.01); A61K 31/13 (2013.01); A61P 25/28 (2018.01)] 20 Claims
 
1. A method of therapeutic treatment of a neurodegenerative disorder of protein aggregation in a human subject,
which method comprises orally administering to said subject a methylthioninium (MT)-containing compound,
wherein said administration provides a total daily dose of between 20.5 and 60 mg of MT to the subject per day, optionally split into 2 or more doses,
wherein the MT-containing compound is LMTM:

OG Complex Work Unit Chemistry
wherein said neurodegenerative disorder is behavioral-variant frontotemporal dementia (bvFTD), and
wherein the therapeutic treatment is not combined with an acetylcholinesterase inhibitor or an N-methyl-D-aspartate receptor antagonist.